Navigation Links
NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Date:12/14/2007

SOPHIA ANTIPOLIS, France, Dec. 14 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced it has successfully completed the enrollment of 1020 patients in the 302 pivotal phase 3 study for naproxcinod, in-line with projections. Naproxcinod is the Company's lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class. The 302 study is designed to assess naproxcinod's efficacy for treating the signs and symptoms of osteoarthritis and provide additional blood pressure data, which is a key factor for differentiating naproxcinod from existing anti-inflammatory treatments. Efficacy results from this study are anticipated in the third quarter of 2008.

The 302 study represents the largest of the three pivotal phase 3 trials for naproxcinod (the 301, 302 and 303 studies). The 301 study is complete and results were recently presented at the 71st annual meeting of the American College of Rheumatology (ACR), which showed that naproxcinod met all three co-primary efficacy endpoints and demonstrated a similar effect on systolic blood pressure to placebo and a reduction compared to naproxen, a commonly used anti-inflammatory agent. The third and final study (303) is a 13-week trial in patients with osteoarthritis of the hip. Patient enrollment in this trial is well underway, following its initiation in June 2007. Current timelines are that the 303 study should complete enrollment in the second quarter of 2008, with results expected by the end of 2008. NicOx now anticipates the filing of a New Drug Application (NDA) for naproxcinod with the US Food and Drug Administration (FDA) in mid-2009.

"The 302 study is the largest and longest duration trial in our program for naproxcinod and our clinical team has proved its effectiveness in successfully recruiting the targeted number of patients in-line with projected timelines," said Pascal Pfister, Chief Scientific Officer of NicOx. "The 302 study will p
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
5. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Kindred Hospital Houston ... announce the opening of its new outpatient wound ... services to people with chronic, hard to heal ... can lead to amputation, lower leg wounds related ... delayed closure, and traumatic injury wounds which are ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... Boca Pharmacal, Inc. announced today that the ... commercial launch of Hydrocodone Bitartrate and Acetaminophen (5mg/300mg, ... Pharma,s Xodol®. Hydrocodone Bitartrate and Acetaminophen is indicated ... pain (Logo: http://photos.prnewswire.com/prnh/20110127/FL37887LOGO) ABOUT ...
... 27, 2011 The U.S. Food and Drug Administration ... academics, biotechnology companies, and those unfamiliar with the process ... Calif. in collaboration with Keck Graduate Institute. ... co-sponsored by the National Organization of Rare Disorders and ...
Cached Medicine Technology:Fourth FDA Orphan Drug Designation Workshop Scheduled for Feb. 28 - March 1, 2011 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 The ... Copper, Molybdenum, Iron), Form (Chelated & Non Chelated), ... Geography - Global Trends and Forecast to 2018” ... with an analysis and forecasting of the global ... identifies the driving and restraining factors for the ...
(Date:7/13/2014)... July 13, 2014 Fuel additives are ... gasoline, diesel, jet fuel, kerosene, and so on, in ... responsible for reducing the corrosion effects caused by fuels ... added to any fuel, provide economies of scale in ... escalate the overall cost of the fuel products. , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 MarketsandMarkets ... Market [3D Modeling; 3D Scanning; 3D rendering; Layout ... and Analysis (2013 - 2018)”, which analyzes and ... in North America, Western Europe, Eastern Europe, Middle ... report also draws the competitive landscape of the ...
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, 2014 (HealthDay ... with diabetes is being developed to measure sugar levels in ... Scientists at Brown University in Providence, R.I., created the sensor ... metal and a special enzyme that changes color when exposed ... prick their fingers to draw blood to check their blood ...
(Date:7/13/2014)... 13, 2014 Athletes with a certain ... from concussions, according to research presented today at the ... Annual Meeting. The research marks the first of its ... the known physical events that occur after a head ... long allele in the (GT)n genotype were four times ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... ... 25 years experience to the workplace resources company , ... Chicago, IL (PRWEB) April 28, 2010 -- ... behavioral healthcare, work/life services, organizational development and wellness services, welcomes Rick Kronberg ...
... to liver failure in some, British researchers say , ... for a mild high is popular in East Africa ... seen among certain immigrant groups in Great Britain and ... severe liver damage and even death, British researchers report. ...
... effective in less than half of cases, study finds , ... identified vitamin E as a treatment that can provide relief ... the most common chronic liver disease. , "This clearly shows ... nonalcoholic steatohepatitis who don,t have active diabetes," said study author ...
... ... retailer of health and fitness products for people who are serious about ... 2010. ,Established in 2000 in Newcastle-upon-Tyne, originally as a mail order company, ... event by launching a new, even more user-friendly website packed with exciting ...
... with a brain arteriovenous malformation (AVM), an abnormal tangle ... of vessel rupture and bleeding that can cause stroke ... preventative interventions, such as endovascular procedures, surgical resection, or ... on the assumption that unruptured AVMs pose similar risk ...
... Md., April 28, 2010 In a major crackdown, ... operating in the country to close within the past ... against Counterfeit & Substandard Medicines (IMC), the shops were ... primary sources of substandard and counterfeit medicines in the ...
Cached Medicine News:Health News:Rick Kronberg Joins Perspectives Ltd As Director of Clinical Services 2Health News:Chewing Khat Linked to Severe Liver Damage 2Health News:Vitamin E Helps Treat Common Liver Disease 2Health News:Vitamin E Helps Treat Common Liver Disease 3Health News:Slimming Solutions Celebrates 10 Years in Business with the Launch of a New Weight Loss Website 2Health News:Do unruptured brain vessel malformations need preventative surgery? 2Health News:Do unruptured brain vessel malformations need preventative surgery? 3Health News:Cambodia takes action in fight against substandard and counterfeit medicines 2Health News:Cambodia takes action in fight against substandard and counterfeit medicines 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: